Latest Rivastigmine Stories

According to BCC Research’s report, Alzheimer's Disease Therapeutics and Diagnostics: Global Markets, the global market for Alzheimer’s disease reached $10.2 billion in 2012, and is expected to decrease at a compound annual growth rate (CAGR) of -1.5% to reach $9.5 billion in 2017. Wellesley, MA (PRWEB) June 11, 2013 Every second a new person in the United Stated develops Alzheimer’s disease. This astonishing statistic has become a reality for the 5.4 million Americans now...

PARSIPPANY, N.J., March 8, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) today confirmed that it has filed with the U.S. Food and Drug Administration (FDA) an amendment to its Abbreviated New Drug Application (ANDA) for Rivastigmine Transdermal System to include the 13.3 mg per 24 hours dosage strength. Actavis' ANDA product is a generic version of Novartis' Exelon(®) Patch, which is a prescription medicine used to treat people with mild to moderate dementia associated with...

EAST HANOVER, N.J., Sept. 4, 2012 /PRNewswire/ -- The US Food and Drug Administration has approved a higher dose of Exelon(®) Patch (rivastigmine transdermal system) for the treatment of people with mild to moderate Alzheimer's disease. The new 13.3 mg/24 h dosage strength of Exelon Patch provides physicians with a new treatment option for patients who are experiencing a decline in overall function and cognition. "Alzheimer's disease is marked by progressive symptomatic...

- Phase 2b study of a new symptomatic drug - - One-year extension trial of a medical food - - 9-month trial of a dietary supplement - - 18-month study of a home-based care coordination intervention - VANCOUVER, British Columbia, July 18, 2012 /PRNewswire-USNewswire/ -- Results from four clinical trials reported at the Alzheimer's Association International Conference® 2012 (AAIC® 2012) demonstrate the wide variety of approaches being pursued to improve memory, thinking, quality...

BOCA RATON, Fla., June 14, 2012 /PRNewswire/ -- Breckenridge Pharmaceutical, Inc. announced today that Breckenridge and Alembic Pharmaceuticals Limited have settled their Paragraph IV patent litigation with Novartis concerning Rivastigmine Tartrate Capsules, a generic version of Exelon® by Novartis, and that the U.S. Food and Drug Administration (FDA) approved their Abbreviated New Drug Application (ANDA). The companies will launch immediately. Alembic Pharmaceuticals Limited is...

The dementia drug donepezil (Aricept), already widely used to treat mild to moderate Alzheimer's disease, can also help in moderate to severe patients, according to a new report The dementia drug donepezil (Aricept), already widely used to treat mild to moderate Alzheimer's disease, can also help in moderate to severe patients, according to a report funded by the UK Medical Research Council (MRC) and the Alzheimer's Society. The study suggests that extending treatment to this group could...

PARSIPPANY, N.J., Nov. 10, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market rivastigmine transdermal system patches, 4.6 mg/24 hr and 9.5 mg/24 hr. Watson's rivastigmine transdermal system patch is a generic version of Novartis' Exelon(R) Patch. Exelon(R) is a prescription medicine used to...

PITTSBURGH and POTTERS BAR, England, Oct. 25, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its U.K.-based subsidiary has launched Rivastigmine Capsules POM, 1.5 mg, 3 mg, 4.5 mg and 6 mg. This product is the generic version of Novartis' Exelon® Capsules, a treatment for dementia in people with Alzheimer's disease. Mylan is the first company to launch a generic Rivastigmine formulation in the U.K. Mylan Chairman and CEO Robert J. Coury said: "This is the second...

A review of research evidence produced by researchers from the Peninsula Technology Assessment Group, part of the Peninsula College of Medicine and Dentistry, has played a pivotal role in the decision by the National Institute for Health and Clinical Excellence (NICE) to extend the availability of donepezil, galantamine, rivastigmine and memantine for Alzheimer's disease announced today (18th January 2011).A previous appraisal by NICE of these drugs in 2004 approved the use of donepezil,...

DETROIT, July 1 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD) has started shipping rivastigmine tartrate capsules. These products, approved by the US Food and Drug Administration (FDA) for Sun Pharma's Abbreviated New Drug Application (ANDA), are therapeutically equivalent to Exelon® capsules from Novartis. Rivastigmine tartrate is indicated for treatment of mild to moderate Alzheimer's dementia and mild to moderate Parkinson's disease dementia....